


WHAT IS CLAIMED IS:

1. A compound of Formula I:



Formula I

wherein:

- 5 R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are hydrogen, lower alkyl, or -C(O)R;
 in which R is -OR⁹ or -NR⁹R¹⁰, where R⁹ and R¹⁰ are hydrogen or lower alkyl; or
 R¹ and R², R³ and R⁴, R⁵ and R⁶, R⁷ and R⁸, when taken together with the carbon to
 which they are attached, represent carbonyl; or
 R¹ and R⁵, or R¹ and R⁷, or R³ and R⁵, or R³ and R⁷, when taken together form a bridging
10 group -(CR¹²R¹³)_n-, in which n is 1, 2 or 3, and R¹² and R¹³ are independently
 hydrogen or lower alkyl;
 with the proviso that the maximum number of carbonyl groups is 1;
 the maximum number of -C(O)NR⁹R¹⁰ groups is 1; and
 the maximum number of bridging groups is 1;
- 15 T is oxygen, sulfur, or NR¹¹, in which R¹¹ is hydrogen or lower alkyl;
 V is -N<, -CH<, or -NH-CH<;
 X¹ is hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl,
 optionally substituted aryl, or optionally substituted heteroaryl;
- 20 X² is optionally substituted aryl or optionally substituted heteroaryl;
 Y is optionally substituted dihydroheteroaryl; and
 Z¹ and Z² are independently optionally substituted alkylene of 1-4 carbon atoms.

2. A compound of claim 1, wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are independently chosen from hydrogen and methyl and V is -N<.
3. A compound of claim 2, wherein X¹ is optionally substituted aryl and X² is 5 optionally substituted heteroaryl.
4. The compound of claim 3, wherein Z¹ is methylene and Z² is methylene or ethylene.
- 10 5. The compound of claim 4, wherein Y is optionally substituted dihydroheteroaryl in which the hetero atoms are chosen from nitrogen and oxygen.
6. The compound of claim 5, wherein T is oxygen, X¹ is optionally substituted phenyl, and Y is optionally substituted isoxazolyl.
- 15 7. The compound of claim 6, wherein X² is optionally substituted benzothiazolyl.
8. The compound of claim 7, wherein Y is optionally substituted 5-(4,5-dihydroisoxazol-3-yl).
- 20 9. The compound of claim 8, wherein X¹ is 4-(trifluoromethyl)phenyl, X² is 2-methylbenzothiazol-5-yl, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are hydrogen, and Z² is methylene, namely 1-(2-methylbenzothiazol-5-yloxy)-3-[4-(5-[4-(trifluoromethyl)phenyl](4,5-dihydroisoxazol-3-yl)methyl)piperazinyl]propan-2-ol.
- 25 10. An isomer of the compound of claim 9, namely (2R)-1-(2-methylbenzothiazol-5-yloxy)-3-[4-(5-[4-(trifluoromethyl)phenyl](4,5-dihydroisoxazol-3-yl)methyl)piperazinyl]propan-2-ol.
- 30 11. The compound of claim 8, wherein X¹ is 2-(trifluoromethyl)phenyl, X² is 2-methylbenzothiazol-5-yl, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are hydrogen, and Z² is

methylene, namely 3-(2-methylbenzothiazol-5-yloxy)-1-[4-($\{5$ -[2-(trifluoromethyl)phenyl](4,5-dihydroisoxazol-3-yl) $\}$ methyl)piperazinyl]propan-2-ol.

12. An isomer of the compound of claim 11, namely (2R)-3-(2-methylbenzothiazol-5-

5 yloxy)-1-[4-($\{5$ -[2-(trifluoromethyl)phenyl](4,5-dihydroisoxazol-3-yl) $\}$ methyl)piperazinyl]propan-2-ol.

13. The compound of claim 8, wherein X^1 is 4-(trifluoromethyl)phenyl, X^2 is 2-methylbenzothiazol-5-yl, R^1 , R^2 , R^4 , R^5 , R^6 , R^7 , and R^8 are hydrogen, R^3 is (S)-methyl,

10 and Z^2 is methylene, namely 1-[(2S)-2-methyl-4-($\{5$ -[4-(trifluoromethyl)phenyl](4,5-dihydroisoxazol-3-yl) $\}$ methyl)piperazinyl]-3-(2-methylbenzothiazol-5-yloxy)propan-2-ol.

14. An isomer of the compound of claim 13, namely (2R)-1-[(2S)-2-methyl-4-($\{5$ -[4-

15 (trifluoromethyl)phenyl](4,5-dihydroisoxazol-3-yl) $\}$ methyl)piperazinyl]-3-(2-methylbenzothiazol-5-yloxy)propan-2-ol.

15. The compound of claim 8, wherein X^1 is 2-(trifluoromethyl)phenyl, X^2 is 2-methylbenzothiazol-5-yl, R^1 , R^2 , R^4 , R^5 , R^6 , R^7 , and R^8 are hydrogen, R^7 is (S)-methyl,

20 and Z^2 is methylene, namely 1-[(3S)-3-methyl-4-($\{5$ -[2-(trifluoromethyl)phenyl](4,5-dihydroisoxazol-3-yl) $\}$ methyl)piperazinyl]-3-(2-methylbenzothiazol-5-yloxy)propan-2-ol.

16. An isomer of the compound of claim 15, namely (2R)-1-[(3S)-3-methyl-4-($\{5$ -[2-

25 (trifluoromethyl)phenyl](4,5-dihydroisoxazol-3-yl) $\}$ methyl)piperazinyl]-3-(2-methylbenzothiazol-5-yloxy)propan-2-ol.

17. The compound of claim 8, wherein X^1 is 4-(trifluoromethyl)phenyl, X^2 is 2-

methylbenzothiazol-5-yl, R^1 , R^2 , R^4 , R^5 , R^6 , R^7 , and R^8 are hydrogen, R^7 is (S)-methyl,

30 and Z^2 is methylene, namely 3-[(3S)-3-methyl-4-($\{5$ -[4-(trifluoromethyl)phenyl](4,5-

dihydroisoxazol-3-yl)}methyl)piperazinyl]-1-(2-methylbenzothiazol-5-yloxy)propan-2-ol.

18. An isomer of a compound of claim 17, namely (2R)-3-[(3S)-3-methyl-4-($\{5$ -[4-(trifluoromethyl)phenyl](4,5-dihydroisoxazol-3-yl)}methyl)piperazinyl]-1-(2-methylbenzothiazol-5-yloxy)propan-2-ol.

19. The compound of claim 8, wherein X^1 is 2-(trifluoromethyl)phenyl, X^2 is 2-methylbenzothiazol-5-yl, R^1 , R^2 , R^4 , R^5 , R^6 , R^7 , and R^8 are hydrogen, R^3 is (S)-methyl, and Z^2 is methylene, namely 1-[(2S)-2-methyl-4-($\{5$ -[2-(trifluoromethyl)phenyl](4,5-dihydroisoxazol-3-yl)}methyl)piperazinyl]-3-(2-methylbenzothiazol-5-yloxy)propan-2-ol.

20. The isomer of the compound of claim 19, namely (2R)-1-[(2S)-2-methyl-4-($\{5$ -[2-(trifluoromethyl)phenyl](4,5-dihydroisoxazol-3-yl)}methyl)piperazinyl]-3-(2-methylbenzothiazol-5-yloxy)propan-2-ol.

21. The compound of claim 7, wherein Y is optionally substituted 3-(4,5-dihydroisoxazol-5-yl).

22. The compound of claim 21, wherein X^1 is 4-(trifluoromethyl)phenyl, X^2 is 2-methylbenzothiazol-5-yl, R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , and R^8 are hydrogen, and Z^2 is methylene, namely 1-[4-($\{3$ -[4-(trifluoromethyl)phenyl](4,5-dihydroisoxazol-5-yl)}methyl)piperazinyl]-3-(2-methylbenzothiazol-5-yloxy)propan-2-ol.

23. An isomer of the compound of claim 22, namely (2R)-1-[4-($\{(5R)$ -3-[4-(trifluoromethyl)phenyl](4,5-dihydroisoxazol-5-yl)}methyl)piperazinyl]-3-(2-methylbenzothiazol-5-yloxy)propan-2-ol.

30 24. The compound of claim 21, wherein X^1 is 2-(trifluoromethyl)phenyl, X^2 is 2-methylbenzothiazol-5-yl, R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , and R^8 are hydrogen, and Z^2 is

methylene, namely 1-[4-(3-[2-(trifluoromethyl)phenyl](4,5-dihydroisoxazol-5-yl)methyl)piperazinyl]-3-(2-methylbenzothiazol-5-yloxy)propan-2-ol.

25. An isomer of the compound of claim 24, namely (2R)-1-[4-((5R)-3-[2-trifluoromethyl)phenyl](4,5-dihydroisoxazol-5-yl)methyl)piperazinyl]-3-(2-methylbenzothiazol-5-yloxy)propan-2-ol.

26. The compound of claim 21, wherein X¹ is 4-fluorophenyl, X² is 2-methylbenzothiazol-5-yl, R¹, R², R⁴, R⁵, R⁶, R⁷, and R⁸ are hydrogen, R³ is (S)-methyl, and Z² is methylene, namely 1-(4-[(5R)-3-(4-fluorophenyl)(4,5-dihydroisoxazol-5-yl)methyl](3S)-3-methylpiperazinyl)-3-(2-methylbenzothiazol-5-yloxy)propan-2-ol.

27. An isomer of the compound of claim 26, namely (2R)-1-(4-[(5R)-3-(4-fluorophenyl)(4,5-dihydroisoxazol-5-yl)methyl](3S)-3-methylpiperazinyl)-3-(2-methylbenzothiazol-5-yloxy)propan-2-ol.

28. The compound of claim 21, wherein X¹ is phenyl, X² is 2-methylbenzothiazol-5-yl, R¹, R², R⁴, R⁵, R⁶, R⁷, and R⁸ are hydrogen, R³ is (S)-methyl, and Z² is methylene, namely 1-{4-[(5R)-3-phenyl(4,5-dihydroisoxazol-5-yl)methyl](2S)-2-methylpiperazinyl}-3-(2-methylbenzothiazol-5-yloxy)propan-2-ol.

29. An isomer of the compound of claim 28, namely (2R)-1-{4-[(5R)-3-phenyl(4,5-dihydroisoxazol-5-yl)methyl](2S)-2-methylpiperazinyl}-3-(2-methylbenzothiazol-5-yloxy)propan-2-ol.

25

30. A method of treating a disease state chosen from diabetes, damage to skeletal muscles resulting from trauma or shock and a cardiovascular disease in a mammal by administration of a therapeutically effective dose of a compound of claim 1.

31. The method of claim 30, wherein the cardiovascular disease is atrial arrhythmia, intermittent claudication, ventricular arrhythmia, Prinzmetal's (variant) angina, stable angina, unstable angina, congestive heart disease, or myocardial infarction.

5 32. The method of claim 31, wherein the disease state is diabetes.

33. A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of claim 1.